Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Revenue (2016 - 2025)

Arrowhead Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $264.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 10461.32% year-over-year to $264.0 million; the TTM value through Dec 2025 reached $1.1 billion, up 43539.24%, while the annual FY2025 figure was $829.4 million, 23258.15% up from the prior year.
  • Revenue reached $264.0 million in Q4 2025 per ARWR's latest filing, up from $256.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $542.7 million in Q1 2025 to a low of $2.5 million in Q4 2024.
  • Average Revenue over 5 years is $99.9 million, with a median of $32.8 million recorded in 2021.
  • Peak YoY movement for Revenue: crashed 94.32% in 2023, then surged 10461.32% in 2025.
  • A 5-year view of Revenue shows it stood at $27.4 million in 2021, then skyrocketed by 127.95% to $62.5 million in 2022, then plummeted by 94.32% to $3.6 million in 2023, then dropped by 29.6% to $2.5 million in 2024, then soared by 10461.32% to $264.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Revenue are $264.0 million (Q4 2025), $256.5 million (Q3 2025), and $27.8 million (Q2 2025).